|Bid||195.15 x 900|
|Ask||195.42 x 1000|
|Day's Range||189.38 - 195.86|
|52 Week Range||78.41 - 212.55|
|Beta (5Y Monthly)||0.95|
|PE Ratio (TTM)||236.14|
|Earnings Date||Feb 18, 2021 - Feb 22, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||211.50|
Reata's (RETA) omaveloxolone development in Friedreich's Ataxia gets delayed further as FDA proposes additional exploratory analyses to support filing regulatory application for its approval.
Is (RGEN) Outperforming Other Medical Stocks This Year?
Tony Hunt didn't just learn the bioprocessing business as the Repligen CEO. He got his hands dirty over decades of jobs in nearly every aspect of the field.